JW Pharmaceutical highlighted the therapeutic potential of DDC-02 in multiple neurodevelopmental disorder models at WODC USA ...
Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet ...
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announces that it has received ...
Austin, Texas, June 12th, 2026, FinanceWireDisseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: ...
New data presented at EACR 2026 highlighted anti-tumor activity, improved safety characteristics, and pharmacokinetic ...
Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics. But their complex structure poses significant development and safety challenges for biopharma. In this GEN webinar, ...
TORONTO and HAIFA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company ...
JW Pharma announces preclinical results and global development strategy for DDC-02 at World Orphan Drug Congress USA 2026: Seoul, South Korea Saturday, June 13, 2026, 16:00 Hrs [I ...
This Brush Up is sponsored by MilliporeSigma. Learn more about therapeutic synthesis pathways. Drug development is a process that spans many years, from the initial phase of identifying potential drug ...